• 1
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 20052012.
  • 2
    Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabet Med 1985; 2: 4553.
  • 3
    Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263269.
  • 4
    Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010; 123: S3S11.
  • 5
    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405412.
  • 6
    Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 22882298.
  • 7
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J 2006; 332: 7378.
  • 8
    Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P et al. Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 846854.
  • 9
    Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011; 34: 25082514.
  • 10
    International Diabetes Federation. Guideline for Management of Postmeal Glucose. 2007. Available at Last accessed 8 February 2012.
  • 11
    Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011; 13: S25S32.
  • 12
    Ceriello A. The management of postprandial glucose. US Endocrinol 2008; 4: 6367.
  • 13
    Nolan JJ. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia 2010; 53: 12471249.
  • 14
    Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012; 166: 159170.
  • 15
    Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 16
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 30803086.
  • 17
    Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 17361747.
  • 18
    Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 17161730.
  • 19
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 13641379.
  • 20
    Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral anti-diabetic drugs. Diabetes Obes Metab 2008; 10: 11781185.
  • 21
    Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise randomized study. Endocr Pract 2011; 17: 727736.
  • 22
    Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. Int J Clin Pract 2008; 62: 16471653.
  • 23
    Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? Diabetes Metab Res Rev 2007; 23: 257264.
  • 24
    Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 3149.
  • 25
    Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 12541270.
  • 26
    Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther 2011; 13: S33S42.
  • 27
    Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448455.
  • 28
    Kazda C, H\xFClstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145152.
  • 29
    Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22: 374381.
  • 30
    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 20342044.
  • 31
    Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260265.
  • 32
    Lankisch M, Siegmund T, Ferlinz K, Scherbaum WA. Stepwise intensification of a basal insulin glargine regimen in patients close to the metabolic target (A1c 7.0–7.5%): is it worth adding a single daily injection of insulin glulisine? Subanalysis of the OPAL study. Diabetes 2009; 58: A2086PO.
  • 33
    Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single preprandial dose of insulin glulisine while continuing titrated insulin glargine in Type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes Obes Metab 2011; 13: 10201027.
  • 34
    Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011; 17: 395403.
  • 35
    Raccah D, Haak T, Huet D, Monnier L, Penfornis A, Robertson D et al. Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients (pts) with Type 2 diabetes mellitus (T2DM). Diabetes 2010; 59: A555P.
  • 36
    Kalergis M, Pacaud D, Strychar I, Meltzer S, Jones PJ, Yale JF. Optimizing insulin delivery: assessment of three strategies in intensive diabetes management. Diabetes Obes Metab 2000; 2: 299305.
  • 37
    Group DS. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002; 325: 746.
  • 38
    Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 2003; 5: 365369.
  • 39
    Kaufman FR, Halvorson M, Carpenter S. Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes. Diabetes Care 1999; 22: 12521257.
  • 40
    Del Prato S, Nicolucci A, Vespasiani G. Optimising basal plus insulin therapy in type 2 diabetes by telecare assistance for self-monitoring of blood glucose - the ELEONOR study. Diabetologia 2008; 51: S452S453.
  • 41
    Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G. Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine—the ELEONOR study. Diabetes Technol Ther 2012; 14: 175182.
  • 42
    Nicolucci A, Del Prato S, Vespasiani G. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care 2011; 34: 25242526.
  • 43
    Riddle MC, Vlajnic A, Jones BA, Rosenstock J. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine. Diabetes 2011; 60: A0409PP.
  • 44
    Riddle MC, Gao L, Vlajnic A. Clinical characteristics and outcomes of T2DM patients adding 1 to 3 stepwise prandial insulin doses to basal insulin and oral therapy: identifying a problematic subgroup. Diabetes 2012; 61: 14OR.
  • 45
    Fritsche A, Larbig M, Häring H-U, The GINGER Study Group. A basal−bolus regimen of insulin glargine and insulin glulisine results in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-daily premixed insulin in type 2 diabetes patients. Diabetologia 2010; 53: A573.
  • 46
    Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 2025.
  • 47
    Fritsche A, Larbig M, Owens D, Häring HU, GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010; 12: 115123.
  • 48
    Owens DR, van Schalkwyk C, Smith P, Beer S, Goenka N, Bain SC et al. Algorithm for the introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy. Pract Diabetes Int 2009; 26: 7077.